Sale!

Atypical Hemolytic Uremic Syndrome Panel NGS Genetic Test Cost

Original price was: 6,000 د.إ.Current price is: 4,400 د.إ.

-27%

The Atypical Hemolytic Uremic Syndrome (aHUS) Panel NGS Genetic Test, available at DNA Labs UAE for a cost of 4400 AED, is a comprehensive diagnostic tool designed to identify genetic mutations associated with atypical Hemolytic Uremic Syndrome. aHUS is a rare, life-threatening condition characterized by the triad of hemolytic anemia, thrombocytopenia, and acute kidney failure. This condition is primarily caused by genetic abnormalities that lead to uncontrolled activation of the complement system, an essential part of the immune response.

The test employs Next-Generation Sequencing (NGS) technology, a cutting-edge approach that allows for the simultaneous sequencing of multiple genes to detect mutations with high accuracy. This is crucial for conditions like aHUS, where mutations in several different genes can be responsible for the disease. The panel typically includes genes such as CFH, CFI, CD46 (MCP), C3, and others known to be associated with the disease.

By identifying specific genetic mutations, the aHUS Panel NGS Genetic Test can help in confirming a diagnosis of atypical Hemolytic Uremic Syndrome, guiding treatment decisions, and determining the risk of disease recurrence or familial transmission. This information is invaluable for affected individuals and their families for the management of the condition and for making informed healthcare decisions.

Given the complexity and potential severity of aHUS, the availability of this test at DNA Labs UAE represents a significant advancement in the accessibility of personalized medicine and genetic diagnostics in the region.

Home  Sample collection service available

  • 100% accuaret Test Results
  • Ranked as Most trusted Genetic DNA Lab
  • This test is not intended for medical diagnosis or treatment
Guaranteed Safe Checkout

Atypical Hemolytic Uremic Syndrome Panel NGS Genetic Test

Atypical hemolytic uremic syndrome (aHUS) is a rare and life-threatening disorder that affects the kidneys and other organs. DNA Labs UAE offers the Atypical Hemolytic Uremic Syndrome Panel NGS Genetic Test to diagnose this condition and guide treatment decisions.

Test Details

The Atypical Hemolytic Uremic Syndrome Panel NGS Genetic DNA Test is a diagnostic test that uses next-generation sequencing (NGS) technology to analyze a patient’s DNA for genetic mutations associated with aHUS. This highly sensitive and specific test analyzes multiple genes, including complement factor H (CFH), complement factor I (CFI), complement factor B (CFB), complement component 3 (C3), and thrombomodulin (THBD), which play a critical role in regulating the complement system.

Cost and Sample Condition

The cost of the Atypical Hemolytic Uremic Syndrome Panel NGS Genetic Test is AED 4400.0. The test requires a blood sample, extracted DNA, or one drop of blood on an FTA card.

Report Delivery and Method

The report for the Atypical Hemolytic Uremic Syndrome Panel NGS Genetic Test is typically delivered within 3 to 4 weeks. The test utilizes NGS technology for accurate and comprehensive analysis.

Test Type and Test Department

The Atypical Hemolytic Uremic Syndrome Panel NGS Genetic Test falls under the category of Hepatology Nephrology Endocrinology Disorders. It is conducted by general physicians in the Genetics department.

Pre Test Information

Prior to undergoing the Atypical Hemolytic Uremic Syndrome Panel NGS Genetic Test, it is important to provide the clinical history of the patient. Additionally, a genetic counseling session may be conducted to draw a pedigree chart of family members affected by ADAMTS13, C3, CD46, CD59, CFB, CFH, CFHR1, CFHR2, CFHR3, CFHR5, CFI, CR1, CR2, DGKE, INF2, MMACHC, MMUT, PIGA, PLG, and THBD.

Conclusion

The Atypical Hemolytic Uremic Syndrome Panel NGS Genetic Test offered by DNA Labs UAE is a crucial tool for the diagnosis and management of aHUS. By detecting genetic mutations accurately, this test allows for earlier diagnosis and more targeted treatment, ultimately improving patient outcomes. It can also identify family members who may be at risk of developing aHUS, enabling preventive measures.

 

Test Name Atypical hemolytic uremic syndrome Panel NGS Genetic DNA Test
Components  
Price 4400.0 AED
Sample Condition Blood or Extracted DNA or One drop Blood on FTA Card
Report Delivery 3 to 4 Weeks
Method NGS Technology
Test type Hepatology Nephrology Endocrinology Disorders
Doctor General Physician
Test Department: Genetics
Pre Test Information Clinical History of Patient who is going for Atypical hemolytic uremic syndrome Panel NGS Genetic DNA Test. A Genetic Counselling session to draw a pedigree chart of family members affected with ADAMTS13, C3, CD46, CD59, CFB, CFH, CFHR1, CFHR2, CFHR3, CFHR5, CFI, CR1, CR2, DGKE, INF2, MMACHC, MMUT, PIGA, PLG, THBD
Test Details

Atypical hemolytic uremic syndrome (aHUS) panel NGS genetic DNA test is a diagnostic test that uses next-generation sequencing (NGS) technology to analyze a patient’s DNA for genetic mutations associated with aHUS. aHUS is a rare and life-threatening disorder that affects the kidneys and other organs. It is caused by mutations in genes that regulate the complement system, which is part of the immune system that helps to fight infections.

The aHUS panel NGS genetic DNA test analyzes multiple genes associated with aHUS, including complement factor H (CFH), complement factor I (CFI), complement factor B (CFB), complement component 3 (C3), and thrombomodulin (THBD). These genes play a critical role in regulating the complement system and mutations in any of these genes can lead to uncontrolled activation of the complement system, resulting in damage to the kidneys and other organs.

The aHUS panel NGS genetic DNA test is a highly sensitive and specific test that can detect mutations in these genes with a high degree of accuracy. This test can help to confirm a diagnosis of aHUS and guide treatment decisions. It can also be used to identify family members who may be at risk of developing aHUS due to a genetic mutation.

Overall, the aHUS panel NGS genetic DNA test is an important tool for the diagnosis and management of aHUS. It can help to improve patient outcomes by allowing for earlier diagnosis and more targeted treatment.